All News

CURE® is looking back at the Educated Patient® Multiple Myeloma Summit, a half-day virtual event to educate, inform and connect patients with multiple myeloma to a variety of experts in the field.

A person living with metastatic breast cancer shares a poem regarding how her life changed in an instant, and how she continues to push forward even though her disease is extensive.

Take a look back at CURE®’s Educated Patient® Lung Cancer Summit with this roundup of stories that highlight what was discussed at this half-day virtual event.

A high intensity immunochemotherapy with maintenance therapy led to 93.2% of patients achieving a complete response and 55.6% of patients with progression-free survival at five years.

CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.

A cancer survivor recalls an experience from early on during the COVID-19 pandemic and reiterates how more than a year later, she thinks about those little things.

From a high school track runner learning how to run again after a leg amputation due to bone cancer to a father adopting a healthier lifestyle to lose 115 pounds after losing his wife to ovarian cancer, here’s what’s happening in the cancer landscape this week.

CURE spoke with Dr. Eric Jonasch about the National Comprehensive Cancer Network’s Category 1 recommendation for the combination use of Lenvima plus Keytruda for the treatment of front-line renal cell carcinoma. In particular, how it can impact a patient’s treatment journey.

Researchers found that patients who were never married, had lower educational levels or had comorbidities were less likely to be suggested an autologous hematopoietic cell transplantation, which may underline a need for more informed decision making.

An expert spoke with CURE® about the FDA’s recent approval of Libtayo to treat patients with locally advanced basal cell carcinoma who previously had only one therapy option for locally advanced disease.

Some cancer survivors mark the end of their treatment by getting tattoos, but could that body art cause potential health risks? Here a cancer survivor — who has more than 10 tattoos — shares her perspective.

This week on the CURE® Talks Cancer podcast, we’re chatting with an ovarian cancer survivor and teacher about how she maintained her sense of humor through treatment and why it’s important to remain connected to your friends and family, especially during your darkest moments.

If you missed any part of CURE®’s Educated Patient® Breast Cancer Summit, take a look at this roundup of stories that highlight the expert insight and guidance that was shared throughout the day.

In honor of Adolescent and Young Adult (AYA) Cancer Awareness Week, CURE® compiled some recent news and updates from this field that patients, survivors and caregivers may have missed.

Approximately one year after granting Trodelvy accelerated approval, the Food and Drug Administration granted a regular approval to the antibody-drug conjugate in certain patients with pretreated triple-negative breast cancer.

Men with breast cancer who were treated with Soltamox plus gonadotropin-releasing hormone analogue had a decrease in estradiol levels of 85%, whereas Aromasin plus gonadotropin-releasing hormone analogue reduced these levels by 72%.

Survivor’s guilt is not just felt by individuals who overcome a deadly disease like cancer, writes a cancer caregiver. She explains how she has experienced it too but knows that not all caregivers are as lucky as her.

A once-every-two-week regimen of Erbitux has been approved by the FDA, which provides patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck another treatment option.

In an interview, Dr. Andrew Yee of Massachusetts General Hospital discusses how a multiple myeloma diagnosis affects a patient’s life and how hopeful he is about helping them lead normal lives.

While it may not be the first thing patients think of when diagnosed with cancer, appropriate clothing centered around treatment can help ease their overall experience, according to an expert.

Sorting out symptoms as survivors age can be challenging, writes a cancer survivor. She notes that survivors have special needs that they need to be aware of to make the most of their “new normal.”

Early findings show that glofitamab may be a safe and effective option for patients with pretreated, relapsed/refractory B-cell non-Hodgkin lymphoma.

Pirtobrutinib was safe and effective in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia, some of whom developed intolerance or resistance to previous covalent BTK inhibitors.

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center explains what a myeloma millennial, or ‘myelennial,’ is, and how recent advances in multiple myeloma treatments inspired the term.

On social media, CURE® recently asked its readers to share if they have experienced any side effects from cancer treatment and how they have managed them. Here’s what some of them said.

It makes sense to take stock of cancer treatment — its physical, emotional, and spiritual cost, and what people want out of life going forward. Here, a patient with cancer writes how It’s OK to say, “Cancer treatment sucks and I hate it, even when the big prize, our buddy NED, has taken up residence in our bodies.”

Childhood cancer survivors are at a higher risk of pain and associated functional impairments later in life, study results show. These results, according to experts, highlight the need for routine pain screening in survivors.

Patients with platinum-sensitive relapsed ovarian cancer who underwent surgery then chemotherapy had a progression-free survival of 17.4 months compared with 11.9 months in those who underwent chemotherapy alone.

A “thriver” of triple-negative breast cancer shares a poem to mark the 10th anniversary of her survivorship.

The Food and Drug Administration’s Oncologic Drugs Advisory Committee unanimously voted in favor of waiting for more data before making an approval decision involving the use of Keytruda in early triple-negative breast cancer.